Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of RT-102 in Osteoporosis
August 10, 2022 16:23 ET
|
Rani Therapeutics, LLC
- RT-102 was generally well-tolerated, with no RaniPill™-related adverse events - - Bioavailability of PTH delivered via the RaniPill was found to be 300-400% greater than PTH delivered via...
Rani Therapeutics Enters into $45 Million Loan Agreement to Support Ongoing RaniPill® Platform Advancement and Clinical Pipeline Development
August 08, 2022 08:30 ET
|
Rani Therapeutics, LLC
SAN JOSE, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani Therapeutics Reports First Quarter 2022 Financial Results; Provides Corporate Update
May 11, 2022 16:05 ET
|
Rani Therapeutics, LLC
- Initiated a Phase 1 clinical trial of RT-102 for the treatment of osteoporosis – - Unveiled the high-capacity RaniPill™ HC, capable of delivering payloads of up to 20 mg – - Strengthened Board...
Rani Therapeutics to Present at Upcoming Investor Conferences
May 03, 2022 16:05 ET
|
Rani Therapeutics, LLC
SAN JOSE, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral...
Rani Therapeutics’ RaniPill™ Capsule Named Winner in the Health Category of Fast Company’s 2022 World Changing Ideas Awards
May 03, 2022 07:00 ET
|
Rani Therapeutics, LLC
SAN JOSE, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- The winners of Fast Company’s 2022 World Changing Ideas Awards were announced today, with Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or...
Rani Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
April 07, 2022 16:05 ET
|
Rani Therapeutics, LLC
SAN JOSE, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral...
Rani Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results; Provides Corporate Update
March 29, 2022 16:05 ET
|
Rani Therapeutics, LLC
- Initiated a Phase 1 clinical trial of RT-102 for the potential treatment of osteoporosis - - Unveiled the high-capacity RaniPill™ HC, capable of delivering payloads of up to 20 mg - -...
Rani Therapeutics to Release Fourth Quarter and Full Year 2021 Financial Results on Tuesday, March 29, 2022
March 23, 2022 20:38 ET
|
Rani Therapeutics, LLC
SAN JOSE, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral...
Rani Therapeutics Announces Initiation of Phase 1 Study of RT-102 Oral PTH for Osteoporosis
March 23, 2022 08:00 ET
|
Rani Therapeutics, LLC
SAN JOSE, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral...
Rani Therapeutics Unveils High-Capacity RaniPill™ Device For Oral Delivery of Biologics; Reports Preliminary 2021 Consolidated Financial Results
February 23, 2022 08:00 ET
|
Rani Therapeutics, LLC
- Preclinical data demonstrates new RaniPill™ HC (High Capacity) delivered 500%-plus higher payloads than current RaniPill™ capsule - - Up to 20mg payload has the potential to unlock more than 50...